Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

Autor: Véronique Dorvaux, Marc Delord, Marc Muller, Melanie Mercier, Hacene Zerazhi, Jacques Chapiro, Eric Jourdan, Laurence Legros, Françoise Rigal-Huguet, Iona Vaida, François Guilhot, Alberto Santagostino, Claude Preudhomme, Joelle Guilhot, Valérie Coiteux, Jean-Michel Miclea, Jean-Jacques Kiladjian, Emmanuel Gyan, Aude Charbonnier, Amélie Penot, Eric Deconinck, Franck E. Nicolini, Gabriel Etienne, Hyacinthe Johnson-Ansah, Jean-Claude Chomel, Kamel Ghomari, Nathalie Cambier, Delphine Lebon, Viviane Dubruille, Sylvie Glaisner, Philippe Rousselot, Loïc Fouillard, Alain Delmer, Bertrand Joly, Pascal Lenain, Claude-Eric Bulabois, Martine Escoffre Barbe, Christian Berthou, Isabelle Plantier, Delphine Rea, Marc G. Berger, Magda Alexis, Francois-Xavier Mahon, Pascale Cony-Makhoul, Ludovic Lhermitte, Lydia Roy, Jean-Michel Cayuela, Denis Caillot, Anne Vekhoff, Martine Gardembas, Bertrand Pollet, Agnès-Paule Guerci-Bresler, Yazid Arkam, Hervé Maisonneuve, Frédéric Maloisel

Publikováno v: Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, ⟨10.1038/s41375-020-01117-w⟩
Leukemia, Springer Nature, 2021, ⟨10.1038/s41375-020-01117-w⟩

The STI571 prospective randomised trial (SPIRIT) French trial is a four-arm study comparing imatinib (IM) 400 mg versus IM 600 mg, IM 400 mg + cytarabine (AraC), and IM 400 mg + pegylated interferon alpha2a (PegIFN-α2a) for the front-line treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e82d474ec7e8650bf9829473b30a0c5
https://hal.uca.fr/hal-03122967

Analysis of the Processing of Seven Human Tumor Antigens by Intermediate Proteasomes

Autor: Jacques Chapiro, Vincent Stroobant, Benoît Guillaume, Didier Colau, Marie-Pierre Bousquet-Dubouch, Alexandre Dalet, Nicolas Parmentier, Benoît Van den Eynde

Publikováno v: The Journal of Immunology. 189:3538-3547

We recently described two proteasome subtypes that are intermediate between the standard proteasome and the immunoproteasome. They contain only one (β5i) or two (β1i and β5i) of the three inducible catalytic subunits of the immunoproteasome. They

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09d8423bcadd0fe859144e78043cda61
https://doi.org/10.4049/jimmunol.1103213

Tumor-specific shared antigenic peptides recognized by human T cells

Autor: Pierre van der Bruggen, Benoît Van den Eynde, Francis Brasseur, Pascal Chaux, Vincent Stroobant, Erwin S. Schultz, Thierry Boon, Jacques Chapiro, Yi Zhang, Christophe Panichelli

Publikováno v: Immunological Reviews. 188:51-64

The first tumor-specific shared antigens and the cancer-germline genes that code for these antigens were identified with antitumor cytolytic T lymphocytes obtained from cancer patients. A few HLA class I-restricted antigenic peptides were identified

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c2666fcab7231e33ae5bb26ab86460c6
https://doi.org/10.1034/j.1600-065x.2002.18806.x

Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules

Autor: Grégory Parvizi, Jacques Chapiro, Nicolas Parmentier, Vincent Stroobant, Ivan Théate, Didier Colau, Benoît Guillaume, Marie-Pierre Bousquet-Dubouch, Benoît Van den Eynde, Benoit Van Holle

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, no. 43, p. 18599-18604 (2010)

Most antigenic peptides presented by MHC class I molecules result from the degradation of intracellular proteins by the proteasome. In lymphoid tissues and cells exposed to IFNγ, the standard proteasome is replaced by the immunoproteasome, in which

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f28b60bcc9f59ec76f517f6cd14d6552
https://europepmc.org/articles/PMC2972972/

Production of an antigenic peptide by insulin-degrading enzyme

Autor: Didier Colau, Sandra Morel, Jacques Chapiro, Nicolas Parmentier, Vincent Stroobant, Peter van Endert, Benoît Van den Eynde, Philippe de Diesbach

Publikováno v: Nature immunology. 11(5)

Most antigenic peptides presented by major histocompatibility complex (MHC) class I molecules are produced by the proteasome. Here we show that a proteasome-independent peptide derived from the human tumor protein MAGE-A3 is produced directly by insu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f9946e46c60daea4769830ff849c9dd
https://pubmed.ncbi.nlm.nih.gov/20364150